Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ADGM Stock Forecast 2026-2027
$0.53
Current Price
$12.22M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ADGM Price Targets
+654.7%
To High Target of $4.00
+466.0%
To Median Target of $3.00
+466.0%
To Low Target of $3.00
ADGM Price Momentum
-7.0%
1 Week Change
-24.3%
1 Month Change
-64.7%
1 Year Change
-49.0%
Year-to-Date Change
-79.5%
From 52W High of $2.58
+1.9%
From 52W Low of $0.52
📊 TOP ANALYST CALLS
Did ADGM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Adagio Medical is one of their latest high-conviction picks.
Latest ADGM Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ADGM has a bullish consensus with a median price target of $3.00 (ranging from $3.00 to $4.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $0.53, the median forecast implies a 466.0% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Alex Nowark at LUCID CAPITAL MARKETS, suggesting a 466.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADGM Analyst Ratings
3
Buy
0
Hold
0
Sell
ADGM Price Target Range
Low
$3.00
Average
$3.00
High
$4.00
Current: $0.53
Latest ADGM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADGM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | Alex Nowark | Buy | Initiates | $3.00 |
| Apr 14, 2026 | Piper Sandler | Overweight | Initiates | $N/A | |
| Dec 2, 2025 | Lake Street | Buy | Initiates | $N/A |
Adagio Medical Holdings, Inc Common Stock (ADGM) Competitors
The following stocks are similar to Adagio Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ADGM
Adagio Medical
mkt cap
12.66M
Adagio Medical Holdings, Inc Common Stock (ADGM) Financial Data
Adagio Medical Holdings, Inc Common Stock has a market capitalization of $12.22M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -268.9%.
Valuation Metrics
Market Cap
$12.22M
Enterprise Value
$24.06M
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+109.6%
Current Ratio
1.8x
Debt/Equity
420.8x
ROE
-268.9%
ROA
-30.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Adagio Medical Holdings, Inc Common Stock (ADGM) Business Model
About Adagio Medical Holdings, Inc Common Stock
What They Do
Develops catheter ablation technologies for cardiac arrhythmias.
Business Model
The company generates revenue by developing and commercializing innovative cryoablation systems designed for the treatment of various cardiac arrhythmias. Its products, which include specialized catheters and accessories, are marketed to medical professionals and institutions in the healthcare sector, focusing on effective solutions for rhythm management.
Additional Information
Founded in 2011 and based in Laguna Hills, California, the company aims to advance next-generation therapies and is actively pursuing clinical evaluations for broader applications in electrophysiology. Its strong emphasis on innovation positions it as a key player in the medical device industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
41
CEO
Mr. Todd Usen
Country
United States
IPO Year
2024
Website
adagiomedical.comAdagio Medical Holdings, Inc Common Stock (ADGM) Latest News & Analysis
Latest News
Quick Summary
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has submitted a PMA application to the FDA for its vCLAS Ventricular Ablation System to treat drug-refractory ventricular tachycardia.
Why It Matters
Adagio Medical's FDA PMA application for a new ablation system could lead to market approval, boosting sales and stock value, and addressing a significant unmet medical need in cardiac care.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Adagio Medical Holdings (Nasdaq: ADGM) reported Q1 2026 financial results and highlighted pivotal FULCRUM-VT trial results presented at the Heart Rhythm Society 2026 conference.
Why It Matters
Adagio Medical's pivotal trial results could indicate strong future revenue growth, affecting stock performance and investor confidence in the company's market position.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) will present at the BofA Securities 2026 Healthcare Conference on May 13, 2026, at 4:35 PM PDT. A webcast will be available online.
Why It Matters
Adagio Medical's presentation at a major healthcare conference highlights its position in a growing market, potentially influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
2 months ago
Quick Summary
Adagio Medical Holdings (Nasdaq: ADGM) reported six-month results from its FULCRUM-VT clinical trial, supporting its FDA application for the vCLAS Ventricular Ablation System.
Why It Matters
Positive clinical trial results can enhance Adagio's chances of FDA approval, potentially boosting stock value and market confidence in its catheter ablation technologies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) will present its Ultra-low Temperature Ablation technologies for scar-related ventricular tachycardia at the Heart Rhythm Society's 2026 conference.
Why It Matters
Adagio's presentation at a key medical conference highlights its innovative technologies, potentially boosting investor confidence and interest in the company's future growth and market position.
Source: Business Wire
Market Sentiment:
Neutral
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
3 months ago
Quick Summary
Adagio Medical Holdings received FDA Investigational Device Exemption approval to expand its FULCRUM-VT trial, assessing the safety and effectiveness of its vCLAS Ultra-Low Temperature Ablation technology.
Why It Matters
FDA approval for Adagio's trial enhances its growth prospects, potentially leading to new revenue streams and increased market confidence, impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ADGM Stock
What is Adagio Medical Holdings, Inc Common Stock's (ADGM) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Adagio Medical Holdings, Inc Common Stock (ADGM) has a median price target of $3.00. The highest price target is $4.00 and the lowest is $3.00.
Is ADGM stock a good investment in 2027?
According to current analyst ratings, ADGM has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADGM stock?
Wall Street analysts predict ADGM stock could reach $3.00 in the next 12 months. This represents a 466.0% increase from the current price of $0.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adagio Medical Holdings, Inc Common Stock's business model?
The company generates revenue by developing and commercializing innovative cryoablation systems designed for the treatment of various cardiac arrhythmias. Its products, which include specialized catheters and accessories, are marketed to medical professionals and institutions in the healthcare sector, focusing on effective solutions for rhythm management.
What is the highest forecasted price for ADGM Adagio Medical Holdings, Inc Common Stock?
The highest price target for ADGM is $4.00 from at , which represents a 654.7% increase from the current price of $0.53.
What is the lowest forecasted price for ADGM Adagio Medical Holdings, Inc Common Stock?
The lowest price target for ADGM is $3.00 from Alex Nowark at LUCID CAPITAL MARKETS, which represents a 466.0% increase from the current price of $0.53.
What is the overall ADGM consensus from analysts for Adagio Medical Holdings, Inc Common Stock?
The overall analyst consensus for ADGM is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are ADGM stock price projections?
Stock price projections, including those for Adagio Medical Holdings, Inc Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:03 AM UTC